Navigation Links
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Date:9/3/2014

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, September 10 at 11:30am ET (8:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Reports Second Quarter 2014 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
3. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
4. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
5. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
6. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
8. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
9. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
10. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
11. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... "Today, MHA and mental health advocates ... systems reform legislation in more than fifty years. We applaud the bipartisan action ... elected officials to improving mental health services and supports in our nation. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children ... bodies, a researcher at the Icahn School of Medicine at Mount Sinai has ... found that when young children are exposed to secondhand marijuana smoke, measurable amounts ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the release of Smart Device Remote Control through a new partnership with Splashtop ... platforms and strengthens its mobile solutions to help businesses maximize their uptime and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million ... considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, ...
(Date:12/7/2016)... ... 07, 2016 , ... It is vital for any lab to secure funding, ... The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to ... to operate in a GLP (Good Laboratory Practice) fashion. , With features designed to ...
Breaking Medicine News(10 mins):